These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20130429)

  • 1. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer.
    Arpino G; De Angelis C; Giuliano M; Giordano A; Falato C; De Laurentiis M; De Placido S
    Oncology; 2009; 77 Suppl 1():23-37. PubMed ID: 20130429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies in estrogen receptor-positive breast cancer.
    Johnston SR
    Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to endocrine therapy in breast cancer.
    Kurebayashi J
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
    Johnston SR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
    Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
    Giuliano M; Schifp R; Osborne CK; Trivedi MV
    Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endocrine treatment in premenopausal early breast cancer.
    Orlando L; Fedele P; Cinefra M; Sponziello F; Calvani N; Chetrì MC; Rizzo P; D'Amico M; Schiavone P; Portaluri M; Criscuolo M; Burlizzi S; Cinieri S
    Oncology; 2009; 77 Suppl 1():9-13. PubMed ID: 20130426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
    Johnston SR
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.